ArticleMaterials today. Bio2026
Three-dimensional (3D) culture-primed placental mesenchymal stem cells decrease cellular heterogeneity, significantly enhancing osteogenesis via improving mitochondrial function.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesenchymal stem cells (MSCs) hold significant promise for bone tissue engineering, with adult bone marrow-derived MSCs (BMMSCs) widely used but limited by invasive harvesting and senescence-related osteogenic decline. Fetal-origin placental MSCs (PMSCs) offer a non-invasive and highly proliferative alternative, though their osteogenic capacity remains inconsistently reported. Because mitochondrial activity is closely linked to osteogenesis, and culture conditions strongly influence MSC function, we investigated how three-dimensional (3D) culture differentially modulates PMSCs and BMMSCs. Transcriptomic analyses revealed significant enrichment of cell adhesion and mitochondria-related pathways in PMSCs vs. BMMSCs; functional validation demonstrated larger viable spheroid formation and further augmentation of higher baseline mitochondrial activity in 3D-cultured PMSCs, along with upregulation of key osteogenic markers RUNX2 and osteoprotegerin. Surprisingly, even short-term 3D-priming led to elevated mitochondrial and osteogenic capacity in PMSCs but not BMMSCs. Single-cell RNA sequencing of PMSCs revealed that 3D culture promotes homogeneity, enriching for high mitochondrial- and osteogenic-expressing cell clusters. Functionally, inhibition of mitochondrial function suppressed osteogenic differentiation in 3D-primed PMSCs. Our findings reveal more robust baseline PMSC mitochondrial activity which can be further enhanced by even short-term, 1 day of 3D culture to significantly improve osteogenic commitment, demonstrating a practical strategy to improve MSC-based therapies for bone regeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.